Mitoxantrone-induced suicidal erythrocyte death

Cell Physiol Biochem. 2014;34(5):1756-67. doi: 10.1159/000366376. Epub 2014 Nov 12.

Abstract

Background/aims: Mitoxantrone, a cytotoxic drug used for the treatment of malignancy and multiple sclerosis, is at least in part effective by triggering apoptosis. Similar to apoptosis of nucleated cells, erythrocytes may enter eryptosis, a type of suicidal cell death. Hallmarks of eryptosis are cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Signalling involved in eryptosis include Ca(2+)-entry, ceramide formation and oxidative stress.

Methods: Cell volume was estimated from forward scatter, phosphatidylserine-exposure from annexin V binding, formation of reactive oxidant species (ROS) from 2',7'-dichlorodihydrofluorescein-diacetate fluorescence, and ceramide abundance from binding of fluorescent antibodies in flow cytometry.

Results: A 48 hours exposure to mitoxantrone was followed by significant decrease of forward scatter (≥ 5 μg/ml mitoxantrone) and increase of annexin-V-binding (≥ 10 μg/ml mitoxantrone), effects paralleled by significant increases of ROS formation (25 μg/ml mitoxantrone) and ceramide abundance (25 μg/ml mitoxantrone). The effect of mitoxantrone was not significantly modified by nominal absence of extracellular Ca(2+) but significantly blunted by the antioxidant N-acetylcysteine (1 mM).

Conclusions: Mitoxantrone triggers cell membrane scrambling, an effect not requiring entry of extracellular Ca(2+) but at least partially due to formation of ROS and ceramide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / pharmacology
  • Annexin A5 / metabolism
  • Apoptosis / drug effects
  • Calcium / metabolism
  • Cell Death / drug effects*
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Cell Size / drug effects
  • Ceramides / metabolism
  • Erythrocytes / drug effects*
  • Erythrocytes / metabolism
  • Fluoresceins / pharmacology
  • Humans
  • Mitoxantrone / pharmacology*
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / metabolism
  • Oxidative Stress / drug effects
  • Phosphatidylserines / metabolism
  • Reactive Oxygen Species / metabolism

Substances

  • Annexin A5
  • Ceramides
  • Fluoresceins
  • Phosphatidylserines
  • Reactive Oxygen Species
  • 2',7'-dichlorodihydrofluorescein
  • Mitoxantrone
  • Calcium
  • Acetylcysteine